BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 33909232)

  • 1. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
    Thein KZ; Piha-Paul SA; Tsimberidou A; Karp DD; Janku F; Zarifa A; Shah J; Milton DR; Bean S; McQuinn L; Gong J; Colen R; Carter BW; Subbiah V; Ogbonna DC; Pant S; Meric-Bernstam F; Naing A
    Invest New Drugs; 2021 Oct; 39(5):1357-1365. PubMed ID: 33909232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
    Thein KZ; Karp DD; Tsimberidou A; Gong J; Sulovic S; Shah J; Milton DR; Hong DS; Janku F; McQuinn L; Stephen BA; Colen R; Carter BW; Yap TA; Piha-Paul SA; Fu S; Meric-Bernstam F; Naing A
    Invest New Drugs; 2022 Apr; 40(2):290-299. PubMed ID: 34562230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.
    Peterson TJ; Orozco J; Buege M
    Ann Pharmacother; 2020 Jun; 54(6):577-582. PubMed ID: 31793336
    [No Abstract]   [Full Text] [Related]  

  • 4. A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
    Rubinstein MM; Grisham RN; Cadoo K; Kyi C; Tew WP; Friedman CF; O'Cearbhaill RE; Zamarin D; Zhou Q; Iasonos A; Nikolovski I; Xu H; Soldan KN; Caird I; Martin M; Guillen J; Eid KT; Aghajanian C; Makker V
    Gynecol Oncol; 2021 Jan; 160(1):71-76. PubMed ID: 33139041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
    Vergote IB; Lund B; Peen U; Umajuridze Z; Mau-Sorensen M; Kranich A; Van Nieuwenhuysen E; Haslund C; Nottrup T; Han SN; Concin N; Unger TJ; Chai Y; Au N; Rashal T; Joshi A; Crochiere M; Landesman Y; Shah J; Shacham S; Kauffman M; Mirza MR
    Gynecol Oncol; 2020 Feb; 156(2):308-314. PubMed ID: 31822399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
    Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
    J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors.
    Thein KZ; Piha-Paul SA; Tsimberidou A; Karp DD; Janku F; Fu S; Subbiah V; Hong DS; Yap TA; Shah J; Milton DR; McQuinn L; Gong J; Tran Y; Carter BW; Colen R; Meric-Bernstam F; Naing A
    Exp Hematol Oncol; 2021 Dec; 10(1):59. PubMed ID: 34965890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
    Westin SN; Fu S; Tsimberidou A; Piha-Paul S; Akhmedzhanov F; Yilmaz B; McQuinn L; Brink AL; Gong J; Leung CH; Lin H; Hong DS; Pant S; Carter B; Jazaeri A; Gershenson D; Sood AK; Coleman RL; Shah J; Meric-Bernstam F; Naing A
    Gynecol Oncol; 2023 Jan; 168():76-82. PubMed ID: 36423446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
    Kalakonda N; Maerevoet M; Cavallo F; Follows G; Goy A; Vermaat JSP; Casasnovas O; Hamad N; Zijlstra JM; Bakhshi S; Bouabdallah R; Choquet S; Gurion R; Hill B; Jaeger U; Sancho JM; Schuster M; Thieblemont C; De la Cruz F; Egyed M; Mishra S; Offner F; Vassilakopoulos TP; Warzocha K; McCarthy D; Ma X; Corona K; Saint-Martin JR; Chang H; Landesman Y; Joshi A; Wang H; Shah J; Shacham S; Kauffman M; Van Den Neste E; Canales MA
    Lancet Haematol; 2020 Jul; 7(7):e511-e522. PubMed ID: 32589977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
    Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
    Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
    Chari A; Vogl DT; Gavriatopoulou M; Nooka AK; Yee AJ; Huff CA; Moreau P; Dingli D; Cole C; Lonial S; Dimopoulos M; Stewart AK; Richter J; Vij R; Tuchman S; Raab MS; Weisel KC; Delforge M; Cornell RF; Kaminetzky D; Hoffman JE; Costa LJ; Parker TL; Levy M; Schreder M; Meuleman N; Frenzel L; Mohty M; Choquet S; Schiller G; Comenzo RL; Engelhardt M; Illmer T; Vlummens P; Doyen C; Facon T; Karlin L; Perrot A; Podar K; Kauffman MG; Shacham S; Li L; Tang S; Picklesimer C; Saint-Martin JR; Crochiere M; Chang H; Parekh S; Landesman Y; Shah J; Richardson PG; Jagannath S
    N Engl J Med; 2019 Aug; 381(8):727-738. PubMed ID: 31433920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
    Martínez Sánchez MP; Megías-Vericat JE; Rodríguez-Veiga R; Vives S; Bergua JM; Torrent A; Suárez-Varela S; Boluda B; Martínez-López J; Cano-Ferri I; Acuña-Cruz E; Torres-Miñana L; Martín-Herreros B; Serrano A; Sempere A; Barragán E; Sargas C; Sanz M; Martínez-Cuadrón D; Montesinos P;
    Ann Hematol; 2021 Jun; 100(6):1497-1508. PubMed ID: 33914097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selinexor for the treatment of multiple myeloma.
    Podar K; Shah J; Chari A; Richardson PG; Jagannath S
    Expert Opin Pharmacother; 2020 Mar; 21(4):399-408. PubMed ID: 31957504
    [No Abstract]   [Full Text] [Related]  

  • 15. First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.
    Abdul Razak AR; Mau-Soerensen M; Gabrail NY; Gerecitano JF; Shields AF; Unger TJ; Saint-Martin JR; Carlson R; Landesman Y; McCauley D; Rashal T; Lassen U; Kim R; Stayner LA; Mirza MR; Kauffman M; Shacham S; Mahipal A
    J Clin Oncol; 2016 Dec; 34(34):4142-4150. PubMed ID: 26926685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
    Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS).
    Lewin J; Malone E; Al-Ezzi E; Fasih S; Pedersen P; Accardi S; Gupta A; Abdul Razak A
    Eur J Cancer; 2021 Feb; 144():360-367. PubMed ID: 33418486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL.
    Nilsson S; Stein A; Rolfo C; Kranich AL; Mann J; Papadimitriou K; Theile S; Amberg S; Bokemeyer C
    Curr Cancer Drug Targets; 2020; 20(10):811-817. PubMed ID: 32598257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.
    Gounder MM; Zer A; Tap WD; Salah S; Dickson MA; Gupta AA; Keohan ML; Loong HH; D'Angelo SP; Baker S; Condy M; Nyquist-Schultz K; Tanner L; Erinjeri JP; Jasmine FH; Friedlander S; Carlson R; Unger TJ; Saint-Martin JR; Rashal T; Ellis J; Kauffman M; Shacham S; Schwartz GK; Abdul Razak AR
    J Clin Oncol; 2016 Sep; 34(26):3166-74. PubMed ID: 27458288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.